Virility Medical is a privately held, Israeli, medical device start-up company, setting out to enhance sexual well-being. Its large and rapidly growing market is expected grow at 9% CAGR and reach $3B by 2024. Virility has gained robust clinical evidence and secured a US patent for its technology. The company led by a team of highly experienced executives, among them are CEO Mr. David Salton, Chairperson Mr. Ron Mayron, former CEO of Teva Israel Pharmaceutical Industries, and backed by renowned industrialist Mr. Mori Arkin. Virility is expecting to gain CE marking and FDA approval by Q2 2021.
Virility Medical has developed the vPATCH, a clinically proven, drug-free, patented, intimate skin patch for the treatment of premature ejaculation. The vPATCH is applied to the male perineum and delivers low-intensity electrical stimulation during intercourse which immediately postpones ejaculation. The product is intended for single use and is discarded after use. Product’s advanced version, the vSMART, provides the user with personalization capabilities, based on its digital health platform.
The vPATCH is a climax control device which provides men with a drug-free and immediate effect solution to rapid ejaculation.